Journal
PATHOLOGY INTERNATIONAL
Volume 62, Issue 5, Pages 303-308Publisher
WILEY
DOI: 10.1111/j.1440-1827.2012.02789.x
Keywords
antigen presentation; beta2-microglobulin; breast cancer; Immune escape; MHC class I
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Ministry of Health, labor and Welfare of Japan
- Grants-in-Aid for Scientific Research [21249025, 24659592, 23590427, 21590401, 22659075] Funding Source: KAKEN
Ask authors/readers for more resources
A novel monoclonal anti-pan human leukocyte antigen (HLA) class I heavy chain antibody, EMR8-5, was established. It could detect HLA-A, -B, and -C antigens in formalin-fixed paraffin embedded tissues. By immunohistochemical staining using the EMR8-5 antibody, various cancer tissues from 246 cases were examined for HLA class I expression. It was found that HLA class I expression was decreased in 20% to 42% of the cases of lung cancer, hepatocellular carcinoma, colon cancer, renal cell carcinoma, and urothelial carcinoma. In contrast, 85% of breast cancer cases had loss of or decreased HLA class I expression. Of the 35 breast cancer cases that had decreased HLA class I heavy chain expression, 33 (94%) also had decreased beta2-microglobulin expression detected by immunohistochemical staining. It was suggested that HLA class I down-regulation might be a common characteristic of breast cancer mostly caused by the down-regulation of beta2-microglobulin expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available